| Project/Area Number |
15K06875
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
Iyama Satoshi 札幌医科大学, 医学部, 助教 (50398319)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
佐藤 勉 札幌医科大学, 医学部, 講師 (40404602)
小船 雅義 札幌医科大学, 医学部, 准教授 (90336389)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 多発性骨髄腫 / DPP8/9 / DPP |
|---|
| Outline of Final Research Achievements |
Recently, the prognosis of patients with multiple myeloma (MM) has considerably improved due to the use of autologous hematopoietic stem cell transplantation and the introduction of new agents such as the immunomodulatory drugs, proteasome inhibitors. However, no curable treatment is available. We have previously shown that the DPP8/9 inhibitor, 1G244, induced MM cells to cell death by apoptosis. Hence, we demonstrated efficacy for treating MM with DPP8/9 inhibitor.
|
